Share-based Payment Arrangement, Expense of Celldex Therapeutics, Inc. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Celldex Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Celldex Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,801,000, a 8.5% decline year-over-year.
  • Celldex Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $37,088,000, a 17% increase year-over-year.
  • Celldex Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $34,242,000, a 43% increase from 2023.
  • Celldex Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $23,890,000, a 53% increase from 2022.
  • Celldex Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,611,000, a 74% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Celldex Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $37,088,000 $8,801,000 -$819,000 -8.5% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $37,907,000 $9,191,000 +$1,551,000 +20% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $36,356,000 $9,316,000 +$2,114,000 +29% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $34,242,000 $9,780,000 +$2,568,000 +36% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $31,674,000 $9,620,000 +$2,499,000 +35% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $29,175,000 $7,640,000 +$2,423,000 +46% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $26,752,000 $7,202,000 +$2,862,000 +66% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $23,890,000 $7,212,000 +$2,704,000 +60% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $21,186,000 $7,121,000 +$2,625,000 +58% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $18,561,000 $5,217,000 +$1,763,000 +51% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $16,798,000 $4,340,000 +$1,187,000 +38% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $15,611,000 $4,508,000 +$1,368,000 +44% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $14,243,000 $4,496,000 +$1,467,000 +48% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $12,776,000 $3,454,000 +$1,945,000 +129% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $10,831,000 $3,153,000 +$1,878,000 +147% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $8,953,000 $3,140,000 +$1,884,000 +150% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $7,069,000 $3,029,000 +$1,779,000 +142% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $5,290,000 $1,509,000 +$787,000 +109% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $4,503,000 $1,275,000 +$588,000 +86% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $3,915,000 $1,256,000 +$569,000 +83% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $3,346,000 $1,250,000 +$543,000 +77% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $2,803,000 $722,000 -$742,000 -51% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $3,545,000 $687,000 -$1,006,000 -59% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $4,551,000 $687,000 -$1,065,000 -61% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $5,616,000 $707,000 -$1,086,000 -61% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $6,702,000 $1,464,000 -$584,000 -29% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $7,286,000 $1,693,000 -$795,000 -32% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $8,081,000 $1,752,000 -$832,000 -32% 01 Oct 2018 31 Dec 2018 10-K 29 Mar 2021 2020 FY
Q3 2018 $8,913,000 $1,793,000 -$946,000 -35% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $9,859,000 $2,048,000 -$1,402,000 -41% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $11,261,000 $2,488,000 -$1,051,000 -30% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $12,312,000 $2,584,000 -$1,024,000 -28% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2020 2019 FY
Q3 2017 $13,336,000 $2,739,000 -$1,057,000 -28% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $14,393,000 $3,450,000 -$523,000 -13% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $14,916,000 $3,539,000 -$401,000 -10% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $15,317,000 $3,608,000 -$490,000 -12% 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
Q3 2016 $15,807,000 $3,796,000 -$72,000 -1.9% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $15,879,000 $3,973,000 +$1,446,000 +57% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $14,433,000 $3,940,000 +$1,659,000 +73% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $12,774,000 $4,098,000 +$1,965,000 +92% 01 Oct 2015 31 Dec 2015 10-K 07 Mar 2018 2017 FY
Q3 2015 $10,809,000 $3,868,000 +$1,910,000 +98% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $8,899,000 $2,527,000 +$1,016,000 +67% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $7,883,000 $2,281,000 +$1,031,000 +82% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $6,852,000 $2,133,000 +$985,000 +86% 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2017 2016 FY
Q3 2014 $5,867,000 $1,958,000 -$58,000 -2.9% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $5,925,000 $1,511,000 +$835,000 +124% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $5,090,000 $1,250,000 +$542,000 +77% 01 Jan 2014 31 Mar 2014 10-Q 29 Apr 2015 2015 Q1
Q4 2013 $4,548,000 $1,148,000 +$464,000 +68% 01 Oct 2013 31 Dec 2013 10-K/A 25 Feb 2016 2015 FY
Q3 2013 $4,084,000 $2,016,000 +$1,491,000 +284% 01 Jul 2013 30 Sep 2013 10-Q 05 Nov 2014 2014 Q3
Q2 2013 $2,593,000 $676,000 +$228,000 +51% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $2,365,000 $708,000 +$67,000 +10% 01 Jan 2013 31 Mar 2013 10-Q 01 May 2014 2014 Q1
Q4 2012 $2,298,000 $684,000 01 Oct 2012 31 Dec 2012 10-K 24 Feb 2015 2014 FY
Q3 2012 $525,000 -$45,000 -7.9% 01 Jul 2012 30 Sep 2012 10-Q 08 Nov 2013 2013 Q3
Q2 2012 $448,000 -$105,000 -19% 01 Apr 2012 30 Jun 2012 10-Q 06 Aug 2013 2013 Q2
Q1 2012 $641,000 01 Jan 2012 31 Mar 2012 10-Q 03 May 2013 2013 Q1
Q3 2011 $570,000 01 Jul 2011 30 Sep 2011 10-Q 02 Nov 2012 2012 Q3
Q2 2011 $553,000 01 Apr 2011 30 Jun 2011 10-Q 09 Aug 2012 2012 Q2

Celldex Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $34,242,000 +$10,352,000 +43% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $23,890,000 +$8,279,000 +53% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $15,611,000 +$6,658,000 +74% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $8,953,000 +$5,038,000 +129% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $3,915,000 -$636,000 -14% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $4,551,000 -$3,530,000 -44% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $8,081,000 -$4,231,000 -34% 01 Jan 2018 31 Dec 2018 10-K 29 Mar 2021 2020 FY
2017 $12,312,000 -$3,005,000 -20% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020 2019 FY
2016 $15,317,000 +$2,543,000 +20% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
2015 $12,774,000 +$5,922,000 +86% 01 Jan 2015 31 Dec 2015 10-K 07 Mar 2018 2017 FY
2014 $6,852,000 +$2,304,000 +51% 01 Jan 2014 31 Dec 2014 10-K 14 Mar 2017 2016 FY
2013 $4,548,000 +$2,250,000 +98% 01 Jan 2013 31 Dec 2013 10-K/A 25 Feb 2016 2015 FY
2012 $2,298,000 -$44,000 -1.9% 01 Jan 2012 31 Dec 2012 10-K 24 Feb 2015 2014 FY
2011 $2,342,000 -$460,000 -16% 01 Jan 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
2010 $2,802,000 01 Jan 2010 31 Dec 2010 10-K 08 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.